Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?

Table 2 Gem in combination with targeted therapy

Phase III trial	Combination	No. of patient	OS (mo)	P value	PFS	P value	ORR (%)	P value
Moore et al[76]	Gem ± Erlotinib	569	6.24 vs 5.91	0.038	3.75 vs 3.55	0.004	8.6 vs 8.0	NS
Philip et al[79]	Gem ± Cetuximab	745	6.3 vs 5.9	0.23	3.4 vs 3.0	0.18	12 vs 14	0.59
Kindler et al[83]	Gem ± BEV	602	5.8 vs 5.9	0.95	3.8 vs 2.9	0.07	13 vs 10	NS
Van Cutsem et al[84]	Gem + Erlotinib ± BEV	607	7.1 vs 6.0	0.2087	4.6 vs 3.6	0.0002	13.5 vs 8.6	0.057
Goncalves et al[87]	Gem ± Sorafenib	104	8.5 vs 9.2	0.146	3.8 vs 5.6	0.601	NR	NR

OS: Overall survival; PFS: Progression-free survival; ORR: Objective response rate rate; Gem: Gemcitabine; BEV: Bevacizumab; NR: Not reported; NS: Not significant.